BUTYL-BIGUANIDES REDUCE SERUM HDL-CHOLESTEROL CONCENTRATION

Publisher Summary This chapter discusses a study to examine the effect of butyl-biguanides on serum high-density lipoproteins (HDL)-cholesterol (HDL-Ch) concentration. A group of 50 patients with still untreated hyperlipoproteinemia were selected. All of them participated in the control tests for 3 months and throughout this period, they were taking daily 3 × 150 mg Adebit (butyl-biguanide). Their body weight remained unchanged. As persons suffering from liver and kidney diseases and from congestive heart failure are inclined to lactic acid acidosis induced by biguanides, no patients of this type were included in the experimental group. Patients suffering from hyperlipoproteinemia type V and those suffering from hyperlipoproteinemia type IV and having a triglyceride level above 11.4 mmol/1 were also excluded from the experimental group. In all patients, the following tests were carried out: serum cholesterol and triglyceride, lipoprotein electrophoresis, blood sugar, serum uric acid, and HDL-Ch by the precipitation method with phosphotungstic acid–MgCl 2 . The results demonstrated a very significant decrease of the HDL-Ch level. The administration of Adebit did not affect favorably the cholesterol and TG levels of the serum.